Tevogen (TVGN) Non-Current Assets (2021 - 2026)
Tevogen's (TVGN) quarterly Non-Current Assets came in at $2.8 million in Q1 2026, up 179.29% on a YoY basis from $995371.0 in Q1 2025, and down 2.22% quarter-over-quarter from $2.8 million in Q4 2025.
Analysis
Tevogen (TVGN) Non-Current Assets (2021 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Non-Current Assets for 6 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 179.29% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (up 174.18% YoY), and the FY2025 full-year result was $2.8 million, up 158.29% from the prior year.
- Non-Current Assets declined to $2.8 million in Q1 2026 per TVGN's latest filing, from $2.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $356.9 million in Q4 2022 and bottomed at $761755.0 in Q3 2024.
- Historically, Non-Current Assets has averaged $88.9 million across 5 years, with a median of $2.8 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets slumped 98.94% in 2023, then jumped 211.38% in 2025.
- Over 5 years, Non-Current Assets stood at $356.9 million in 2022, then plunged by 98.94% to $3.8 million in 2023, then tumbled by 70.9% to $1.1 million in 2024, then jumped by 158.29% to $2.8 million in 2025, then declined by 2.22% to $2.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.8 million, $2.8 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 441.00 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 279.00 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 451.27 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 523.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 150.83 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 207.76 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 35.91 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 964.69 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 238.14 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 995,371.00 |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 761,755.00 |
| Jun 30, 2024 | 863,496.00 |
| Mar 31, 2024 | 963,486.00 |
| Dec 31, 2023 | 3.78 Mn |
| Sep 30, 2023 | 26.01 Mn |
| Jun 30, 2023 | 25.68 Mn |
| Mar 31, 2023 | 25.37 Mn |
| Dec 31, 2022 | 356.86 Mn |
| Sep 30, 2022 | 354.12 Mn |
| Jun 30, 2022 | 352.38 Mn |
| Mar 31, 2022 | 352.10 Mn |
| Dec 31, 2021 | 352.06 Mn |